Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
Income from Continuing Operations
Nektar Therapeutics
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Nektar Therapeutics
NASDAQ:NKTR
|
Income from Continuing Operations
-$168.3m
|
CAGR 3-Years
30%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-12%
|
||
Johnson & Johnson
NYSE:JNJ
|
Income from Continuing Operations
$14.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-1%
|
||
Bristol-Myers Squibb Co
NYSE:BMY
|
Income from Continuing Operations
-$7.2B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Pfizer Inc
NYSE:PFE
|
Income from Continuing Operations
$4.3B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-9%
|
||
Merck & Co Inc
NYSE:MRK
|
Income from Continuing Operations
$12.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
||
Eli Lilly and Co
NYSE:LLY
|
Income from Continuing Operations
$8.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
12%
|
Nektar Therapeutics
Glance View
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
See Also
What is Nektar Therapeutics's Income from Continuing Operations?
Income from Continuing Operations
-168.3m
USD
Based on the financial report for Sep 30, 2024, Nektar Therapeutics's Income from Continuing Operations amounts to -168.3m USD.
What is Nektar Therapeutics's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-12%
Over the last year, the Income from Continuing Operations growth was 43%. The average annual Income from Continuing Operations growth rates for Nektar Therapeutics have been 30% over the past three years , 17% over the past five years , and -12% over the past ten years .